← Back to headlines
GSK Acquires Nuvalent for $11 Billion to Boost Cancer Pipeline
Pharmaceutical giant GSK has announced an $11 billion acquisition of Nuvalent, a move aimed at significantly strengthening its pipeline of cancer treatment drugs and expanding its oncology portfolio.
9 Jun, 09:28 — 9 Jun, 09:28
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Greek Diaspora Protests Amazon Over Kindle's Lack of Greek Language Support
13m ago
Antique Farmers' Group Innovates with 'Pancit-Pancitan' Noodles
19m ago
SpaceX Valuation Nears $1.8 Trillion Amid IPO Buzz and Wall Street Interest
20m ago